Greenleaf Trust Trims Stock Position in GSK plc (NYSE:GSK)

Greenleaf Trust lessened its stake in GSK plc (NYSE:GSK) by 31.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,356 shares of the pharmaceutical company’s stock after selling 4,808 shares during the period. Greenleaf Trust’s holdings in GSK were worth $384,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. FinTrust Capital Advisors LLC grew its stake in GSK by 6.9% in the 3rd quarter. FinTrust Capital Advisors LLC now owns 4,346 shares of the pharmaceutical company’s stock worth $158,000 after buying an additional 281 shares in the last quarter. UMB Bank n.a. lifted its holdings in shares of GSK by 4.8% in the 3rd quarter. UMB Bank n.a. now owns 6,462 shares of the pharmaceutical company’s stock worth $234,000 after acquiring an additional 297 shares during the last quarter. KCS Wealth Advisory lifted its holdings in shares of GSK by 1.5% in the 3rd quarter. KCS Wealth Advisory now owns 21,391 shares of the pharmaceutical company’s stock worth $775,000 after acquiring an additional 314 shares during the last quarter. Caprock Group LLC lifted its holdings in shares of GSK by 2.8% in the 4th quarter. Caprock Group LLC now owns 11,513 shares of the pharmaceutical company’s stock worth $430,000 after acquiring an additional 317 shares during the last quarter. Finally, Horizon Bancorp Inc. IN lifted its holdings in shares of GSK by 8.9% in the 4th quarter. Horizon Bancorp Inc. IN now owns 3,961 shares of the pharmaceutical company’s stock worth $147,000 after acquiring an additional 323 shares during the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Trading Up 1.6 %

NYSE:GSK opened at $41.24 on Wednesday. The company has a fifty day moving average of $41.88 and a 200 day moving average of $38.90. GSK plc has a 52 week low of $33.33 and a 52 week high of $43.84. The company has a quick ratio of 0.62, a current ratio of 0.88 and a debt-to-equity ratio of 1.19. The firm has a market capitalization of $85.47 billion, a P/E ratio of 13.70, a P/E/G ratio of 1.40 and a beta of 0.64.

GSK (NYSE:GSK) last posted its quarterly earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.72 EPS for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.04). GSK had a net margin of 16.24% and a return on equity of 51.45%. The firm had revenue of $10 billion for the quarter, compared to the consensus estimate of $9.79 billion. On average, research analysts predict that GSK plc will post 4.03 earnings per share for the current year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, April 11th. Shareholders of record on Friday, February 23rd were issued a $0.3564 dividend. The ex-dividend date was Thursday, February 22nd. This is a positive change from GSK’s previous quarterly dividend of $0.34. This represents a $1.43 annualized dividend and a yield of 3.46%. GSK’s dividend payout ratio is 52.82%.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on GSK shares. Jefferies Financial Group upgraded shares of GSK from a “hold” rating to a “buy” rating in a report on Wednesday, January 3rd. Guggenheim upgraded shares of GSK from a “neutral” rating to a “buy” rating in a report on Monday, March 4th. Morgan Stanley started coverage on shares of GSK in a report on Tuesday, January 23rd. They issued an “equal weight” rating for the company. Finally, Citigroup upgraded shares of GSK from a “neutral” rating to a “buy” rating in a report on Tuesday, February 13th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, GSK presently has an average rating of “Moderate Buy”.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.